ntermittent claudication (IC) caused by peripheral arterial disease (PAD) is one of the common symptoms in the elderly population. 1 In patients with IC, worsening claudication is found in 10-20% at 5 years 2 and revascularization procedures are performed in some patients. Endovascular therapy (EVT) for symptomatic PAD has become common due to improved diagnosis and technological advances. Good patency rates have been shown in patients with PAD in the iliac artery, 3,4 and short -mid-term patency rates in the femoral artery are expected to improve with use of a nitinol stent 5-7 in combination with pharmacotherapy. 8, 9 Some PAD patients, however, have poor outcomes, and the Trans-Atlantic Intersociety Consensus (TASC) II guidelines indicate differences in long-term outcome between those with IC and critical limb ischemia (CLI). 1 Therefore, these diseases require separate investigation. Few studies have examined the outcomes of patients with claudication who underwent EVT, and >10-year outcome is not fully known. In the present study we evaluated >10-year prognosis for limb and life in patients with IC who underwent EVT.
Study Outcome Measures
The primary outcome measure was primary patency rate after treatment, and the secondary outcome measures were mortality rate, freedom from major adverse cardiovascular events (MACE: included death, non-fatal myocardial infarction (MI) and stroke), freedom from any repeat revascularization of treated limb and incidence of CLI or leg amputation after procedure.
Definitions
MI was defined by a significant elevation of serum biomarkers (troponin T >0.1 ng/ml or creatinine kinase levels twice normal) or new Q waves on the electrocardiogram. Coronary artery disease (CAD) was defined as >50% stenosis in coronary vessel on angiography, history of coronary artery bypass graft surgery, or previous MI. Stroke was defined as cerebral stroke that persisted for ≥24 h and indicated the occurrence of a neurological deficit. Chronic kidney disease (CKD) was regarded as present when creatinine clearance estimated by Cockcroft -Gould formula was <60 ml/min. Left ventricular (LV) dysfunction was defined as <40% of LV ejection fraction, Below-the-knee (BTK) artery disease was assessed on angiography before or after the procedure. BTK disease consisted of 2 or more occlusions of the following arteries: anterotibial artery, peroneal artery, or posterotibial artery.
Procedural success was defined as a residual stenosis of <30% and the absence of a flow-limiting dissection on angiography. Primary patency was defined as treated vessel without re-stenosis and repeat revascularization. Re-stenosis was defined as >2.4 peak systolic velocity ratio on duplex ultrasound 10 or >50% stenosis on angiography or computed tomography. Any repeat revascularization included any percutaneous or surgical revascularization of any segment of both lower extremities.
Statistical Analysis
Data are reported as mean ± SD. Continuous variables were examined on unpaired t-test. Categorical variables were compared by chi-square test. Survival curves were estimated by the Kaplan -Meier method and compared with the log -rank test. Cox multivariate regression analysis was used to determine predictors for mortality and primary patency. Prespecified risk factors (age, sex, diabetes, hypertension, hyperlipidemia, smoker, stroke, CAD, CKD, LV dysfunction, prior MI, history of heart failure, aortic aneurysm, femoropopliteal [FP] lesion, BTK disease, use of stent, procedure success, chronic total occlusion, TASC II C/D, pre-procedural anklebrachial index, lesion length, reference vessel diameter, calcified lesion, use of medication such as aspirin, thienopyridines, statins, and angiotensin-converting enzyme inhibitors or angiotensin-receptor blocker) with P<0.05 on Cox univariate models were entered into the multivariable Cox regression model. P<0.05 was considered statistically significant.
Results

Patient and Lesion Characteristics
The age of the 271 patients ranged from 37 to 88 years old (mean: 67.3±6.5 years). The characteristics of the patients and lesions are listed in Table 1 . Focal lesions in larger 
Initial Outcome
The procedure was successfully completed in 252 patients (93.0%). The success rate per lesion was 93.1% (308/331) and stent implantation was performed in 63 (19%) for flowlimiting dissection. The procedure success rate for iliac lesions was significantly higher than that for FP lesions (96.6% vs 87.0%; P=0.0009).
Prognosis for Limbs
Clinical follow-up was performed for 249 patients (93%). The follow-up period for the 139 survivors was 11.7±2.9 years (range, 1-19 years). Of the 252 patients who underwent successful EVT, overall primary patency was 82.1%, 79.0% and 77.8% at 5, 10 and 15 years, respectively. Freedom from any repeat revascularization was 73.7%, 63.7% and 53.3% at 5, 10 and 15 years after procedure (Figure 1) . Although target lesion revascularization was required in 17.9%, 21.0% and 22.2% at 5, 10 and 15 years, revascularization for a new lesion was also required in 9.4%, 20.3% and 32.3% at 5, 10 and 15 years, showing an almost linear increase (Figure 2A) . In a lesion-based analysis, primary patency after EVT for FP lesion was significantly lower compared to that for iliac lesion ( Figure 2B ). Significant differences of primary patency were also found between the TASC II class A/B and C/D (Figure 2C) .
On multivariate analysis performed in a Cox hazards model, TASC II class C/D and an involving FP lesion were independent predictors of primary patency in patients with a successful procedure ( Table 2) . Stent use was not a predictor of primary patency (hazard ratio [HR]=1.44, 95% confidence interval [CI]=0.86-2.4, P=0.17). Of the 245 patients who were followed for 10 years, 85 (34.7%) had required revascularization in the lower extremities up to 10 years after onset. CLI was found in 11 patients (4.5%) and major amputation was performed in 4 of these (1.6%; Figure 3 ).
Prognosis for Survival
The survival curve for the entire group is shown in Figure 4 . Freedom from all-cause mortality (cardiac death) occurred in 73.4% (85.4%) at 5 years, 57.8% (77.5%) at 10 years, and 43.2% (67.1%) at 15 years. Freedom from MACE occurred in 69.8%, 48.8% and 33.5% at 5, 10 and 15 years. During the observation period, 132 patients died. Cardiac death occurred in 64 patients (48%), of whom 41 died of acute coronary syndrome or sudden death. Non-cardiac vascular causes accounted for 18% of deaths, including stroke (9%), ruptured aortic aneurysm (4%) and renal failure (5%). Cardiovascular death accounted for 66% ( Table 3) .
On multivariate analysis performed with pre-specified risk factors in a Cox proportional hazards model, the independent predictors for all-cause death were age, diabetes, BTK disease, LV dysfunction, CKD and CAD ( Table 4) . Successful EVT was not an independent predictor for long-term outcome (HR=0.98, 95%CI=0.54-1.77, P=0.94). Lipid parameters and glycemic parameters also had no influence on survival. Of the 245 patients followed for 10 years, 109 (44%) died and 31 (13%) developed non-fatal MI and stroke up to 10 years after onset. Almost half of the deaths were cardiac deaths and 18% were due to non-cardiac vascular causes (Figure 3) . 
Long-Term Outcome After Endovascular Therapy
Discussion
In the present study overall primary patency in patients with IC who underwent EVT was good because of simple lesion characteristics, but their mortality was poor. At that time, the expected survival rate of the age-adjusted normal population of Japan was 89.0% and 70.2% at 5 and 10 years, respectively. The survival rate of the present study population (73.4% at 5 years, 57.8% at 10 years) was obviously lower compared to that of the normal population.
Procedure success was achieved in 201 iliac and 107 FP lesions. Selective stenting (ie, stenting only in a lesion with a pressure gradient after balloon angioplasty) has been reported to be favorable in EVT for iliac lesions, 11 with persistence of the effect in long-term outcomes (5-8 years). 12, 13 Factors associated with long-term patency include TASC II class C/D, an ipsilateral femoral lesion, CLI, hemodialysis, and smoking. 14 Stents were implanted in 48 lesions in the present study (13.9%, 28/201), but use of stent was not a predictor of primary patency for iliac lesion, in contrast to TASC II class A/B (HR=0.22, 95%CI=0.11-0.44, P<0.001) .68) were not predictors of long-term vessel patency. Stents were applied to 19 lesions, using a Palmaz stent for bail-out due to flowlimiting dissection in all cases (at that time only Palmaz stent was available in Japan). It is unclear if outcomes using Palmaz stents in FP lesions are superior to balloon angioplasty 15 and we were unable to address this issue in the present study. Recently the efficacy of nitinol stent for FP lesion has been reported. Use of nitinol stent for simple lesions may lead to elimination of the need for re-stenosis after the procedure. 16 We found CLI in 11 patients (4.5%) and major amputation was performed in 4 of these (1.6%). Spontaneous CLI has been found in 1-2% of claudicant patients up to 5 years, 2 and occurred in 4.5% (11 patients) within 10 years in the present study. The small number of CLI patients and the absence of a comparative group receiving oral treatment make it difficult to evaluate whether EVT for patients with IC can prevent CLI.
PAD patients are frequently complicated with CAD, and almost half of patients with symptomatic PAD are complicated with CAD. 17 In the present study CAD was indicated in 184 patients (67.9%). Of these 184 patients, 59 (21.8%, 59/ 271) required revascularization and underwent percutaneous (53 patients) or surgical (6 patients) coronary revascularization. PAD patients also frequently develop MI and stroke. 18 In the present study the accumulated incidences of MI and cerebral infarction were 9.7% and 7.5% at 5 years after surgery, 15.3% and 16.2% at 10 years, and 20.8% and 23.2% at 15 years, respectively, showing linear increases. Therefore, systemic vascular management of the lower extremities, coronary artery and cerebral vessels is recommended for PAD patients.
There are several limitations that may have affected the clinical outcomes. First, the study was performed as a singlecenter retrospective analysis. A large-scale, prospective, multicenter study is required to verify the present findings. Second, clinical follow-up angiography or duplex ultrasound were not dictated by the strict protocol. Similarly, repeat revascularization was performed in accordance with clinically driven symptoms. Finally, lipid-lowering therapy with statins has been shown to reduce mortality and cardiovascular events, 19,20 but this information was not available at the time of treatment. Consequently, oral administration of statins was low (11%) in the present patients, and a higher rate may have decreased the mortality.
Conclusion
The outcomes of claudicant patients due to iliofemoral artery disease who underwent EVT were good, but their prognosis was poor. Factors related to long-term patency in the lower extremities differ from those related to late mortality. Table 2 . † Defined as <40% of LVEF.
